ADCT · NYSE
ADC Therapeutics SA (ADCT) Stock Price & Fundamentals
ADC Therapeutics SA (ADCT) closed at $750.23 on Oct 9, 2026, down 0.17% from the previous close of $751.50.
Share price, past year
1Y +13.19%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $750.23 |
| Sep 30, 2026 | $753.44 |
| Aug 31, 2026 | $779.42 |
| Jul 31, 2026 | $779.70 |
| Jun 30, 2026 | $745.47 |
| May 29, 2026 | $768.44 |
| Apr 30, 2026 | $773.97 |
| Mar 31, 2026 | $775.35 |
| Feb 27, 2026 | $810.83 |
| Jan 30, 2026 | $762.65 |
| Dec 31, 2025 | $724.19 |
| Nov 28, 2025 | $696.03 |
| Oct 31, 2025 | $688.14 |
Key statistics
- Market cap
- $95.61B
- P/E (TTM)
- —
- EPS (TTM)
- —
- Revenue (TTM)
- $84.54M
- Net income (TTM)
- −$96.91M
- Shares outstanding
- 127.4M
- Dividend yield
- —
- 52-week range
- $658.34 – $836.59
ADC Therapeutics SA's market cap is $95.61B, based on a share price of $750.23 and 127.4M shares outstanding as of Jun 30, 2026.
Financials
ADC Therapeutics SA reported revenue of $81.36M for fiscal 2025, up 14.85% from fiscal 2024.
ADC Therapeutics SA reported a net loss of $142.62M in fiscal 2025.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $81.36M | +14.9% | −$142.62M | −175.3% | −$1.12 | −$141.44M |
| FY2024ended Dec 31, 2024 | $70.84M | +2.6% | −$157.85M | −222.8% | −$1.62 | −$124.70M |
| FY2023ended Dec 31, 2023 | $69.06M | −7.8% | −$240.05M | −347.6% | −$2.94 | −$121.90M |
| FY2022ended Dec 31, 2022 | $74.91M | — | −$157.13M | −209.8% | −$2.01 | −$139.00M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $18.63M | −$16.57M | −$0.11 |
| Q1 FY2026ended Mar 31, 2026 | $20.03M | −$32.97M | −$0.21 |
| Q4 FY2025ended Dec 31, 2025 | $30.12M | −$6.41M | — |
| Q3 FY2025ended Sep 30, 2025 | $15.75M | −$40.97M | −$0.30 |
| Q2 FY2025ended Jun 30, 2025 | $18.09M | −$56.65M | −$0.50 |
| Q1 FY2025ended Mar 31, 2025 | $17.40M | −$38.60M | −$0.36 |
| Q4 FY2024ended Dec 31, 2024 | $17.94M | −$30.73M | — |
| Q3 FY2024ended Sep 30, 2024 | $18.02M | −$43.97M | −$0.42 |
Company profile
- Name
- ADC Therapeutics SA
- Ticker
- ADCT
- Exchange
- NYSE
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- Biopole, Route De La Corniche 3b, Epalinges, V8 1066
- Incorporated in
- V8
- Fiscal year ends
- December
- SEC CIK
- 0001771910
Recent SEC filings
- Aug 13, 2026
- Aug 13, 2026
- Jul 2, 2026
- Jun 24, 2026
- Jun 3, 2026
- Jun 2, 2026
- May 4, 2026
- May 4, 2026
Frequently asked questions
What is ADC Therapeutics SA's stock price?
ADC Therapeutics SA (ADCT) closed at $750.23 on Oct 9, 2026, down 0.17% from the previous close of $751.50.
What is ADC Therapeutics SA's market cap?
ADC Therapeutics SA's market cap is $95.61B, based on a share price of $750.23 and 127.4M shares outstanding as of Jun 30, 2026.
How much revenue does ADC Therapeutics SA make?
ADC Therapeutics SA reported revenue of $81.36M for fiscal 2025, up 14.85% from fiscal 2024.
Does ADC Therapeutics SA pay a dividend?
ADC Therapeutics SA's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from ADC Therapeutics SA's filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures